What is PinPoint Testing?
PinPoint Testing, LLC operates at the intersection of advanced manufacturing and clinical consulting, providing essential workflow solutions for analytical laboratories. By maintaining CLIA and ANAB-ISO/IEC 17025:2017 accreditations, the firm ensures that its clinical and forensic testing services meet the highest regulatory standards. Their flagship product, the ToxBox, exemplifies their commitment to operational efficiency, offering a streamlined approach to forensic toxicology, chemistry, and industrial hygiene. By integrating innovative design with rigorous testing protocols, PinPoint Testing addresses the critical need for data integrity and throughput in environmental and clinical sectors.
How much funding has PinPoint Testing raised?
PinPoint Testing has raised a total of $1.3M across 2 funding rounds:
Private Equity
$1.2M
Debt
$104K
Private Equity (2017): $1.2M, investors not publicly disclosed
Debt (2021): $104K led by PPP
Key Investors in PinPoint Testing
PPP
Public-Private Partnership
Undisclosed Investor
A private equity participant providing foundational capital to support the company's initial growth and infrastructure development.
What's next for PinPoint Testing?
With the recent influx of capital, PinPoint Testing is well-positioned to scale its manufacturing capabilities and broaden its footprint in the forensic and clinical toxicology markets. The strategic focus will likely shift toward enhancing the technological infrastructure of the ToxBox platform, ensuring it remains the industry standard for laboratory workflow optimization. As the company navigates this growth phase, the emphasis will remain on maintaining its stringent accreditation standards while exploring new applications in forensic chemistry and environmental testing. This capital deployment strategy is designed to fortify the company's competitive advantage, ensuring long-term sustainability and market leadership in the analytical services landscape.
See full PinPoint Testing company page
